How to launch a companyIt's been ten days since the merger closed. There are only 32 days or 22 business days until the AGM. The proposed new name for the company should be released soon. Until we see a detailed plan the market could be under pressure? The stock is trading at cash now so it is already pretty cheap. How much cash is left through today and the completion of the merger? How long is the cash expected to last given the expected burnrate for the new company? What key milestones can the cash get the company to that add value before the risk of a dilutive financing? Which development programs will be the focus for funding? What is the regulatory path forward for the assets and where do they stand today? We haven't had much of an update for AEZS's pipeline assets for some time(NMOSD, etc.). How are the near-term revenue generating opportunities that the merger was expected to finance advancing? Powder beta glucan, malted avenanthramide, chewy bar? How will the immune booster be sold? Is there any interest in licensing the diagnostic test with top-line results expected in Q3? The avenanthramide pill clinical trial is before the Data Safety Monitoring Board awaiting clearance for the multi-ascending dose portion of the clinical trial. We could get a news release soon. Has the commissioning of the 50L PGX facility been completed and fine-tuned? This was expected to provide materials for potential partners. Does that mean it is deal time or will a deal wait for completion of the commissioning of the 100L scale-up in Q3 which is the decision point for mass industrialization. An animal trial protocol was also designed for the immune booster as announced last November. Final data from the Angogenesis Foundation could be soon and fibrosis data was sent to be published with the journal Biomaterials. Does the comapny launch a full plan at the AGM or sooner when the proposed name is announced. What about analyst interest?